DIBENZOYL-P-QUINONE DIOXIME
General Information
Mainterm | DIBENZOYL-P-QUINONE DIOXIME |
CAS Reg.No.(or other ID) | 120-52-5 |
Regnum |
177.2600 |
From www.fda.gov
Computed Descriptors
Download SDF2D Structure | |
CID | 67122 |
IUPAC Name | [(4-benzoyloxyiminocyclohexa-2,5-dien-1-ylidene)amino] benzoate |
InChI | InChI=1S/C20H14N2O4/c23-19(15-7-3-1-4-8-15)25-21-17-11-13-18(14-12-17)22-26-20(24)16-9-5-2-6-10-16/h1-14H |
InChI Key | WMVSVUVZSYRWIY-UHFFFAOYSA-N |
Canonical SMILES | C1=CC=C(C=C1)C(=O)ON=C2C=CC(=NOC(=O)C3=CC=CC=C3)C=C2 |
Molecular Formula | C20H14N2O4 |
From Pubchem
Computed Properties
Property Name | Property Value |
---|---|
Molecular Weight | 346.342 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Complexity | 564.0 |
CACTVS Substructure Key Fingerprint | A A A D c c B 7 O A A A A A A A A A A A A A A A A A A A A A A A A A A w Y I A A A A A A A A A B Q A A A H g A E A A A A D A i B m A A w C I A Q A A C o A y D y C A A C A A A k A A A I i A E Q C N g I J j K A F R C A M Q A k w A E I i Y e I y C C O A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A = = |
Topological Polar Surface Area | 77.3 |
Monoisotopic Mass | 346.095 |
Exact Mass | 346.095 |
XLogP3 | None |
XLogP3-AA | 4.1 |
Compound Is Canonicalized | True |
Formal Charge | 0 |
Heavy Atom Count | 26 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Isotope Atom Count | 0 |
Covalently-Bonded Unit Count | 1 |
From Pubchem
ADMET Predicted Profile --- Classification
Model | Result | Probability |
---|---|---|
Absorption | ||
Blood-Brain Barrier | BBB+ | 0.9337 |
Human Intestinal Absorption | HIA+ | 0.9805 |
Caco-2 Permeability | Caco2+ | 0.5630 |
P-glycoprotein Substrate | Non-substrate | 0.7437 |
P-glycoprotein Inhibitor | Non-inhibitor | 0.7223 |
Non-inhibitor | 0.7609 | |
Renal Organic Cation Transporter | Non-inhibitor | 0.8830 |
Distribution | ||
Subcellular localization | Mitochondria | 0.6388 |
Metabolism | ||
CYP450 2C9 Substrate | Non-substrate | 0.6648 |
CYP450 2D6 Substrate | Non-substrate | 0.8612 |
CYP450 3A4 Substrate | Non-substrate | 0.6421 |
CYP450 1A2 Inhibitor | Inhibitor | 0.5880 |
CYP450 2C9 Inhibitor | Non-inhibitor | 0.7186 |
CYP450 2D6 Inhibitor | Non-inhibitor | 0.9472 |
CYP450 2C19 Inhibitor | Non-inhibitor | 0.6407 |
CYP450 3A4 Inhibitor | Non-inhibitor | 0.9079 |
CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.7020 |
Excretion | ||
Toxicity | ||
Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.9763 |
Non-inhibitor | 0.9497 | |
AMES Toxicity | AMES toxic | 0.9107 |
Carcinogens | Carcinogens | 0.5372 |
Fish Toxicity | High FHMT | 0.9902 |
Tetrahymena Pyriformis Toxicity | High TPT | 0.9399 |
Honey Bee Toxicity | Low HBT | 0.5115 |
Biodegradation | Not ready biodegradable | 0.7807 |
Acute Oral Toxicity | III | 0.6494 |
Carcinogenicity (Three-class) | Non-required | 0.4823 |
From admetSAR
ADMET Predicted Profile --- Regression
Model | Value | Unit |
---|---|---|
Absorption | ||
Aqueous solubility | -4.0256 | LogS |
Caco-2 Permeability | 0.8608 | LogPapp, cm/s |
Distribution | ||
Metabolism | ||
Excretion | ||
Toxicity | ||
Rat Acute Toxicity | 2.1330 | LD50, mol/kg |
Fish Toxicity | -0.3471 | pLC50, mg/L |
Tetrahymena Pyriformis Toxicity | 1.1590 | pIGC50, ug/L |
From admetSAR